Using AI Models for Predicting Human Pancreatic Cancer Response to Cell Cycle Targeted Therapy

Pancreatic ductal adenocarcinoma has a very low 5-year survival rate of 13%. Current chemotherapy treatments often fail due to drug resistance and side effects. CDK4/6 inhibitors are a promising approach but lack reliable markers to predict patient response. This project aims to improve treatment by identifying biomarkers that predict how the cancer responds to chemotherapy and CDK4/6 inhibition. Using advanced machine learning models called visible neural networks, we will refine these models to better predict drug responses. Collaboration between experts will test these models on patient samples. The goal is to develop more effective treatments and pave the way for clinical trials in San Diego.